Allarity Therapeutics Inc. (ALLR)
NASDAQ: ALLRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALLR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.56M
- EPS (TTM)
- -$0.79
- Dividend yield
- None
- 52-week range
- 0.769 – 1.84
- Day range
- 0.78 – 0.8905
- Volume / Avg
- 305.15K / 131.74K
- Beta
- —
- Shares outstanding
- 16.00M
52-week range
ALLR stock today
Shares of Allarity Therapeutics (ALLR) finished lower on Nov 20 at $0.785, a drop of 9.25% or $0.08 per share, versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 305.15K shares, a sign of unusually heavy trading. Shares are 57.3% below their 52-week high of $1.84, set on May 27, 2026 and 2.1% above the 52-week low of $0.769, near the bottom of the past year's range.
ALLR is down 27.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 25.9%. Allarity Therapeutics has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Allarity Therapeutics
Company profileAllarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Thomas H. Jensen
- Headquarters
- Tarpon Springs, FL
- Employees
- 7
- Website
- allarity.com
Financial highlights
Full financialsIn fiscal 2025, Allarity Therapeutics generated $320,000 in revenue, up 0.0% from fiscal 2024. Allarity Therapeutics reported a net loss of $11.2 million, compared with a loss of $24.5 million a year earlier. Operating margin was -3939.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $320.00K | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-11.23M | $-24.52M | $-11.90M | $-16.06M | $-26.65M |
| EPS (diluted) | — | — | $-10.26 | $-3,093.42 | $-4.19 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$11.00+1301.27%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.39 vs $-0.21
- Surprise
- -85.71%
ALLR news
All ALLR news- Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045GlobeNewswire
- Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient CohortsGlobeNewswire
- Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial GuidanceGlobeNewswire
- Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring RevenueGlobeNewswire
Allarity Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MCRBSeres Therapeutics Inc. | 1.24 | -6.77% | $12.64M | vs ALLR |
| NEUPNeuphoria Therapeutics Inc. | 2.35 | +1.29% | $12.72M | vs ALLR |
| BOLTBolt Biotherapeutics Inc. | 4.91 | -2.96% | $12.80M | vs ALLR |
| MIRAMIRA Pharmaceuticals Inc. | 0.291 | -20.84% | $12.23M | vs ALLR |
| TVRDTvardi Therapeutics Inc. | 0.9893 | +4.57% | $13.22M | vs ALLR |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs ALLR |
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs ALLR |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs ALLR |
Indexes, lists and sector
Allarity Therapeutics stock FAQ
What is Allarity Therapeutics's stock price today?
ALLR last traded at $0.785 as of Nov 20, 4:00 PM EST, down 9.25% on the day. Prices are delayed at least 15 minutes.
Does Allarity Therapeutics pay a dividend?
No. Allarity Therapeutics does not currently pay a regular cash dividend.
Who is Allarity Therapeutics's CEO?
Mr. Thomas H. Jensen is the chief executive officer of Allarity Therapeutics Inc., which has about 7 employees.
Has ALLR ever split its stock?
Yes. The most recent ALLR stock split was a 1-for-30 split on Sep 11, 2024, one of 4 splits on record.
What is the ALLR 52-week high?
The 52-week high for ALLR is $1.84 and the 52-week low is $0.769. The stock is currently 57.3% below its high.